Addiction Biology
July 2010
Saturnino Spiga, Alessandra Lintas, Michele Migliore et al.
Cannabinoid withdrawal produces a hypofunction of mesencephalic dopamine neurons that impinge upon medium spiny neurons (MSN) of the forebrain. After chronic treatment with two structurally different cannabinoid agonists, Delta(9)-tetrahydrocannabinol and CP55 940 (CP) rats were withdrawn spontaneously and pharmacologically with the CB1 antagonist SR141716A (SR). In these two conditions,...
Pharmacology, Biochemistry, and Behavior
July 2010
Koen B E Böcker, J Gerritsen, Claudine C Hunault et al.
Cannabis intake has been reported to affect cognitive functions such as selective attention. This study addressed the effects of exposure to cannabis with up to 69.4mg Delta(9)-tetrahydrocannabinol (THC) on Event-Related Potentials (ERPs) recorded during a visual selective attention task. Twenty-four participants smoked cannabis cigarettes with four doses of THC on four test days in a...
British Journal of Pharmacology
June 1, 2010
Jürg Gertsch, Roger G Pertwee, Vincenzo Di Marzo
It is intriguing that during human cultural evolution man has detected plant natural products that appear to target key protein receptors of important physiological systems rather selectively. Plants containing such secondary metabolites usually belong to unique chemotaxa, induce potent pharmacological effects and have typically been used for recreational and medicinal purposes or as poisons....
Pharmacology, Biochemistry, and Behavior
June 2010
Abir T. El-Alfy, Kelly Ivey, Keisha Robinson et al.
The antidepressant action of cannabis as well as the interaction between antidepressants and the endocannabinoid system has been reported. This study was conducted to assess the antidepressant-like activity of Delta(9)-THC and other cannabinoids. Cannabinoids were initially evaluated in the mouse tetrad assay to determine doses that do not induce hypothermia or catalepsy. The automated mouse...
British Journal of Pharmacology
June 1, 2010
Daniel T Malone, Matthew N Hill, Tiziana Rubino
Cannabis is one of the most widely used illicit drugs among adolescents, and most users first experiment with it in adolescence. Adolescence is a critical phase for brain development, characterized by neuronal maturation and rearrangement processes, such as myelination, synaptic pruning and dendritic plasticity. The endocannabinoid system plays an important role in fundamental brain...
The British Journal of Psychiatry
May 31, 2010
Cécile Henquet, Jim van Os, Rebecca Kuepper et al.
124 citations
BACKGROUND: Little is known about the experiential dynamics of the interaction between cannabis and vulnerability to psychosis. AIMS: To examine the effects of cannabis on psychotic symptoms and mood in patients with psychosis and healthy controls. METHOD: Patients with a psychotic disorder (n = 42) and healthy controls (n = 38) were followed in their daily lives using a structured...
Neuroscience Letters
May 21, 2010
Peng Huang, Lee-Yuan Liu-Chen, Lynn G Kirby
Marijuana discontinuation has been recently reported to be anxiogenic in humans, which may predict relapse. Limited animal research has been carried out to model this withdrawal-associated negative affect. The current study sought to investigate the potential anxiety-like effects of cannabinoid withdrawal in mice. Male ICR mice were injected s.c. with delta9-tetrahydrocannabinol (THC) at...
Psychiatric News
May 21, 2010
Mark Moran
2 citations
Back to table of contents Previous article Next article Clinical & Research NewsFull AccessCannabis Use, Psychosis Symptoms Show Strong LinkMark MoranMark MoranSearch for more papers by this authorPublished Online:21 May 2010https://doi.org/10.1176/pn.45.10.psychnews_45_10_028AbstractMarijuana use among individuals with schizophrenia is associated with more severe positive psychotic symptoms...
Schizophrenia Research
May 18, 2010
P. DeRosse, Alyson Kaplan, K. Burdick et al.
Objective Despite the controversy surrounding the possible causal link between cannabis use and the onset of schizophrenia (SZ), data seeking to elucidate the effect of cannabis use disorders (CUD) on the clinical presentation of SZ have produced mixed results. Although several studies have suggested that CUD in patients with SZ may be associated with variation in cognitive function, clinical...
Schizophrenia Research
May 14, 2010
S. Sevy, D. Robinson, B. Napolitano et al.
Introduction The purpose of this study is to determine if an earlier age at onset of positive symptoms in schizophrenia is associated with cannabis use disorders (CUD). Methods 49 first-episode schizophrenia subjects with CUD were compared to 51 first-episode schizophrenia subjects with no substance use disorders for demographic and clinical variables. A multivariate logistic regression was...